The combination ERG expression and PTEN loss was statistically associated with GS = 7 prostate tumors (Pearson Chi-Square, p = 0.008) (Table 2), as it was detected in 2/39 (5.1%) tumor foci with GS = 6 and 19/103 (18.4%) with GS = 7, but in only 4/78 (5.1%) with GS ≥ 8. The gene discussed is PTEN; the disease is neoplasm.